Summit Therapeutics PLC Company Profile (LON:SUMM)

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SUMM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.31
  • 50 Day Moving Average: $101.62
  • 200 Day Moving Average: $106.31
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $61.02M
  • Outstanding Shares: 61,324,000
Additional Links:

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
DateFirmActionRatingPrice TargetDetails
1/20/2016N+1 SingerReiterated RatingCorporateView Rating Details
4/2/2015JMP SecuritiesInitiated CoverageOutperformView Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Summit Therapeutics PLC (LON:SUMM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)
Current Year EPS Consensus Estimate: $-38.78 EPS

Dividends

Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (LON:SUMM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2015Valerie AndrewsInsiderBuy10,500GBX 145£15,225
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
DateHeadline
morningstar.co.uk logoSummit Therapeutics Sees Positive Phase I Trial Results For Ezutromid (LON:SUMM)
www.morningstar.co.uk - August 9 at 10:56 AM
4-traders.com logoSummit Therapeutics : Shows Further Positive Trial Data For Ridinilazole (LON:SUMM)
www.4-traders.com - June 22 at 10:58 AM
investors.com logoSummit uses more than gut instinct to prove C.diff antibiotic's worth (LON:SUMM)
www.proactiveinvestors.com - June 22 at 10:58 AM
publicnow.com logoFirst Quarter Financial Results (LON:SUMM)
www.publicnow.com - June 21 at 12:09 PM
4-traders.com logoSummit Therapeutics : Enrols First Patient In Phase II Ezutromid Trial (LON:SUMM)
www.4-traders.com - June 17 at 10:18 AM
investors.com logoSummit Therapeutics recruits first phase II DMD patient (LON:SUMM)
www.proactiveinvestors.com - June 17 at 10:18 AM
seekingalpha.com logo5 Attractive Biotechnology Stocks For Healthy, Long-Term Returns (LON:SUMM)
seekingalpha.com - June 10 at 7:59 PM
sbwire.com logoDuchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2016 - New Market Research Report (LON:SUMM)
www.sbwire.com - June 10 at 7:59 PM
biz.yahoo.com logoQ1 2017 Summit Therapeutics PLC Earnings Release - Time Not Supplied (LON:SUMM)
biz.yahoo.com - June 2 at 7:07 AM
News IconCaldan Therapeutics bolsters senior team (LON:SUMM)
www.pmlive.com - May 31 at 8:02 PM
iii.co.uk logoSummit Therapeutics plc ( SUMM ) (LON:SUMM)
www.iii.co.uk - February 26 at 1:32 PM
finance.yahoo.com logoSummit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease Symptoms (LON:SUMM)
finance.yahoo.com - February 24 at 7:00 AM
News IconWill Edwards thought nothing of his own safety when he saw flames engulfing the car when it burst into flames on the M60 (LON:SUMM)
www.ad-hoc-news.de - February 5 at 3:00 PM
finance.yahoo.com logoSummit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference (LON:SUMM)
finance.yahoo.com - February 3 at 7:00 AM
News IconRecent Broker Updates On Summit Therapeutics Plc (SMMT) - Risers & Fallers (LON:SUMM)
www.risersandfallers.com - January 29 at 2:17 PM
News IconRecent Broker Updates On Summit Therapeutics (LON:SUMM) - Risers & Fallers (LON:SUMM)
www.risersandfallers.com - January 28 at 2:11 PM
News IconOppenheimer Thinks Summit Therapeutics' Stock is Going to Recover - Analyst Ratings (LON:SUMM)
www.analystratings.com - January 26 at 2:15 PM
News IconSummit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infection - pharmabiz.com (LON:SUMM)
www.pharmabiz.com - January 22 at 8:15 PM
News IconSummit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infection (LON:SUMM)
pharmabiz.com - January 22 at 1:13 PM
news.sys-con.com logoPeptide Therapeutics Market Will Rise at a Moderate 2.8% CAGR to Touch US$23.7 ... - SYS-CON Media (press release) (LON:SUMM)
news.sys-con.com - January 21 at 1:26 PM
wallstreet.org logoSummit Therapeutics Gets UK OK to Start Phase 2 Trial of Duchenne Muscular ... - WallStreet.org (LON:SUMM)
www.wallstreet.org - January 21 at 1:26 PM
streetinsider.com logoAyretrade, Inc. (SUMM) Granted Key European Patent for Ridinilazole for Treatment of C. Difficile (LON:SUMM)
www.streetinsider.com - January 21 at 1:26 PM
finanznachrichten.de logoSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial in DMD (LON:SUMM)
www.finanznachrichten.de - January 21 at 1:26 PM
noodls.com logoSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD (LON:SUMM)
www.noodls.com - January 21 at 7:25 AM
News IconSummit Therapeutics Granted Key European Patent - ag-IP-news Agency (LON:SUMM)
www.ag-ip-news.com - January 20 at 1:11 PM
globenewswire.com logoSummit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile ... - GlobeNewswire (press release) (LON:SUMM)
globenewswire.com - January 19 at 7:53 PM
cnn.com logoSummit Therapeutics Granted Key European Patent for Novel Antibiotic ... - CNNMoney (LON:SUMM)
money.cnn.com - January 19 at 12:46 PM
News IconPrice Target Update On Summit Therapeutics Plc (SMMT) - Risers & Fallers (LON:SUMM)
www.risersandfallers.com - January 19 at 12:46 PM
noodls.com logoGrant of Key European Patent for Novel Antibiotic Ridinilazole for Treatment of CDI (LON:SUMM)
www.noodls.com - January 19 at 7:15 AM
finance.yahoo.com logoSummit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection (LON:SUMM)
finance.yahoo.com - January 19 at 7:00 AM
capitalcube.com logoSummit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : January 14, 2016 (LON:SUMM)
www.capitalcube.com - January 14 at 4:34 AM
biz.yahoo.com logoQ3 2016 Summit Therapeutics PLC Earnings Release - Time Not Supplied (LON:SUMM)
biz.yahoo.com - December 17 at 7:07 AM

Social


Last Updated on 8/25/2016 by MarketBeat.com Staff